FDA flags potential VEGF-related safety concern in Summit rejection letter, company downplays risk
The FDA flagged a safety issue in its review of Summit Therapeutics’ and Akeso’s now-rejected cancer drug ivonescimab, raising questions about the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







